Novel approaches including gene editing are creeping towards approval.
How can the company wring the most value from Pyrukynd?
Will upping the dose and changing the primary endpoint pay off?
February will also see an outcome for Gilead's long-acting HIV therapy, and a key FDA panel for me-too checkpoint MAbs.
At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.
Now in Servier’s hands, the Agios-discovered Tibsovo could soon face competition from Forma’s olutasidenib.
The company reports decent data with its Oxbryta follow-on, but still has much to prove.